Journalists

Journalists

Covering current events in science, the environment, technology and health requires a context and reliable sources that respond quickly.

¿Qué me ofrece?

When science hits the headlines, we publish reactions, explanations, and in-depth analysis from reliable sources, capturing both the evidence and the debates. Our library of science journalism resources and the briefings may be of use to you. Consult our directory of research centres.

Icono
Cómo trabajamos

We are on the lookout for any controversial information about science (embargoed or not), in order to react with the agility the media needs. Sign up to receive our embargoed contents, all under the Creative Commons licence. Find out more about how we work here.

Título qué me ofrece
What we offer you
Título cómo trabajamos
How we work

Reaction: mice that confront the aggressor develop greater resilience than those that flee

A study in mice published in the journal Nature has analysed the different responses to aggression and the consequences for subsequent behaviour. In general, animals that confronted the aggressor developed greater resilience than those that fled or avoided the aggressor, and the gain was greater as brain circuits associated with dopamine were activated.

0

Reaction to study claiming that life expectancy recovered in 2021 in some countries, including Spain

Research published in Nature Human Behaviour analyses changes in life expectancy since the advent of covid-19. Its findings show that some countries in western Europe, including Spain, regained some of their lost life expectancy, and others returned to 2019 levels. On the other hand, losses continued in Eastern Europe and the United States.

0

Reactions: EMA gives green light to new dengue vaccine

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation for the tetravalent dengue vaccine (live, attenuated) Takeda. The vaccine is intended to prevent disease caused by dengue virus serotypes 1, 2, 3 and 4 in people aged four years and older. Although an approved vaccine already exists, according to the EMA, this quadrivalent vaccine shows increased protection in children and people over 45 years of age.

0